epinephrine sublingual (P2-101) / PHase Pharmaceuticals - LARVOL DELTA

The U.S. Food and Drug Administration (FDA) has scheduled at least six Prescription Drug User Fee Act (PDUFA) target action dates for January 2026 (GeneOnline) - "Among the decisions expected this month is a review of the first sublingual epinephrine treatment designed for allergic reactions, marking a potential milestone in allergy management."

PDUFA • Allergy